Lead investigator, ASCENT breast cancer trials
Appears in 1 story
Chief of breast oncology, Dana-Farber Cancer Institute
Triple-negative breast cancer is aggressive and short on options. On June 24, 2026, the U.S. Food and Drug Administration (FDA) cleared Gilead Sciences' drug Trodelvy as a first-line treatment, moving a medicine once used only after other drugs failed to the front of the line.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
